Expanding the indications for sacubitril/valsartan to unchartered territories

Int J Cardiol. 2020 Dec 15:321:128. doi: 10.1016/j.ijcard.2020.07.033. Epub 2020 Jul 24.

Authors

Susanne J Maurer¹, Oktay Tutarel²

Affiliations

¹ Department of Electrophysiology, German Heart Centre Munich, Technical University of Munich, Munich, Germany.
² Department of Congenital Heart Disease and Paediatric Cardiology, German Heart Centre Munich, Technical University of Munich, Munich, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany. Electronic address: oktay.tutarel@tum.de.

PMID: 32712111
DOI: 10.1016/j.ijcard.2020.07.033

No abstract available

Keywords: Adult congenital heart diseases; Sacubitril/valsartan, cancer therapy-related cardiomyopathy.

Publication types

Letter
Comment

MeSH terms

Adult
Aminobutyrates
Biphenyl Compounds
Drug Combinations
Heart Defects, Congenital*
Heart Failure* / drug therapy
Humans
Tetrazoles
Valsartan

Substances

Aminobutyrates
Biphenyl Compounds
Drug Combinations
Tetrazoles
Valsartan
sacubitril and valsartan sodium hydrate drug combination